August 2019
2019 Interim Results Presentation
1Copyright© 2019 Innovent Biologics
This presentation includes forward-looking statements. All statements contained in this presentation other than statements of historical facts, including statements regarding future results of
operations and financial position of Innovent Biologics (“Innovent” “we,” “us” or “our”), our business strategy and plans, the clinical development of our product candidates and our objectives for
future operations, are forward-looking statements. The words “anticipate,” believe,” “continue,” “estimate,” “expect,” “intend,” “may,” “will” and similar expressions are intended to identify forward-
looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our
financial condition, results of operations, business strategy, clinical development, short-term and long-term business operations and objectives and financial needs. These forward-looking
statements are subject to a number of risks, uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It
is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual
results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events and trends discussed in
this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.
Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, achievements or events
and circumstances reflected in the forward-looking statements will occur. We are under no duty to update any of these forward-looking statements after the date of this presentation to conform
these statements to actual results or revised expectations, except as required by law. You should, therefore, not rely on these forward-looking statements as representing our views as of any
date subsequent to the date of this presentation.
This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data
involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. Neither we nor any other person makes any representation as to the
accuracy or completeness of such data or undertakes any obligation to update such data after the date of this presentation. In addition, projections, assumptions and estimates of our future
performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.
This presentation may not be all inclusive and may not contain all of the information that you may consider material. Neither Innovent nor any of its affiliates, shareholders, directors, officers,
employees, agents and advisors makes any expressed or implied representation or warranty as to the completeness, fairness, reasonableness of the information contained herein, and none of
them shall accept any responsibility or liability for any loss or damage, whether or not arising from any error or omission in compiling such information or as a result of any party's reliance or use
of such information. By attending or receiving this presentation you acknowledge that you will be solely responsible for your own assessment of our business, the market and our market position
and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of our business.
This presentation is intended solely for investors that are qualified institutional buyers or institutional accredited investors solely for the purposes of familiarizing such investors with Innovent and
determining whether such investors might have an interest in a securities offering contemplated by Innovent . Any such offering of securities will only be made pursuant to an exemption from, or
in a transaction not subject to, the registration requirements of the U.S. Securities Act of 1933, as amended, or by means of a registration statement (including a prospectus) filed with the SEC,
after such registration statement becomes effective. No such registration statement has been filed, or become effective, as of the date of this presentation. This presentation shall not constitute
an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful
prior to registration or qualification under the securities laws of any such state or jurisdiction.
Disclaimer
2Copyright© 2019 Innovent Biologics
Our History
2011.8 Innovent was
established
2012 First IND filed
with the NMPA
2013 Strategic
alliance with
Adimab
2014 First IND
application
was approved
Manufacturing
facility was
built
2015
Strategic
partnership with
Eli Lilly
Passed audit on
GMP system
and production
facility
To develop and commercialize high quality biopharmaceuticals that are affordable to ordinary people
2016 IBI-301,IBI-303, IBI-305
entered Phase III clinical
trials
Passed GMP audits on
drug products system
2017
2018 Listed on HKEX
Filed NDA for IBI-303 (biosimilar
to adalimumab) with NMPA
Tyvyt granted with marketing
approval by the NMPA
Strategic partnership with Incyte
Strategic alliance
with Hanmi
PD-1 monoclonal
antibody IBI-308
entered Phase III
clinical trials 2019
Cover Story of sintilimab
(Tyvyt ) by The Lancet
Haematology
Flied NDA for IBI-305
(biosimilar to bevacizumab)
Filed NDA for IBI-301
(biosimilar to rituximab)
Strategic partnership with
Eli Lilly for diabetes
Inaugural Issue of The
Lancet Rheumatology of
IBI-303 (biosimilar to
adalimumab)
®
®
3Copyright© 2019 Innovent Biologics
Major Accomplishments in 2019
CommercializationClinicalAdvancement
Corporate MilestonePipeline Expansionthrough Partnership
1st LAUNCH AND
COMMERCIALIZATIONTyvyt ® (sintilimab injection) was launched sales on Mar 9, 2019,and achieved RMB 331.6 M sales in 1H 2019. That remarks the company has grown to the commercial phaseof the business cycle and has unleashed the full power of our fully-integrated multi-functionplatform for the discovery, development, manufacture and commercialization of innovativedrugs in a variety of therapeutic areas.
2 NDA SUBMITTED
NDA for IBI-305 (biosimilar to bevacizumab) in Jan 2019 and IBI-301 (biosimilar to rituximab) in Jun 2019
EXPANSION OF
MANUFACTURING FACILITIESSecond manufacturing facility M1b, housing 6x3000L stainless steel bioreactors, have completed GMP commissioning and validation
STRATEGIC PARTNERSHIP
WITH Eli Lilly and CompanyStrategic collaboration with Lillyfor mid-stage potentially global best-in-class diabetes molecule product candidate, OXM3
STRATEGIC PARTNERSHIP
WITH IncyteStrategic collaboration with Incyte(entered in December 2018) for three late-stage first in China, potentially global best-in-class small molecule product candidates, IBI-375(pemigatinib, a novel FGFR inhibitor), IBI-376 (parsaclisib, a novel PI3Kδ inhibitor), IBI-377 (itacitinib, a novel JAK1 inhibitor)
5 IND APPROVED
sintilimab (IBI308F101) China;IBI-318 China; IBI-110 China & US; IBI-315 China
10 TRIALS COMPLETED
FIRST PATIENT DOSINGsintilimab (4 trials); IBI-302 (bispecific Fc fusion protein);IBI-318 (bispecific antibody);IBI-188 (China & US); IBI-101; IBI-306
ORGANIZATION GROWTH
Reached approximately 1,500 employees1
8 REGISTRATION TRIALS ON GOING
3 PHASE III TRIALS COMPLETED
PATIENTS ENROLLMENTIncluding 2L Squamous NSCLC;1L Squamous NSCLC;1L Non-squamous NSCLC of sintilimab
1. As of June 30, 2019
4Copyright© 2019 Innovent Biologics
Clinical advancement since 2019
(1) We and Eli Lilly will co-promote sintilimab (IBI-308) and rituximab (IBI-301) in China
Status (China)
IND
Candidate/
Reference Drug Target(s) Therapeutic Area: Disease Indications Commercial Rights Pre-clinical (Filed) (Accepted)
Phase IPhase II Phase III NDA Launched
sintilimab (IBI-308) PD-1
Oncology: r/r Hodgkin’s lymphoma, 1L and 2Lmelanoma, refractory gastrointestinal cancers, 2L NSCLC, 2L esophageal cancer, 1L and 2L squamous NSCLC, 1L non-squamous NSCLC, r/r NK/T-cell lymphoma, 2L ESCC, 1L gastric cancer, solid tumors, and esophageal carcinoma
Worldwide1
IBI-303 (adalimumab
biosimilar)TNF-alpha
Autoimmune: rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis,ankylosing spondylitis, Crohn’sdisease, ulcerative colitis and psoriasis Worldwide
IBI-305 (bevacizumab
biosimilar)VEGF-A Oncology: r/r NSCLC and metastatic CRC Worldwide
IBI-301 (rituximab
biosimilar)CD20
Oncology: non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis Worldwide1
IBI-377 (itacitinib) JAK1 Graft versus host disease (phase 3 in the US) China
IBI-375 (pemigatinib) FGFR1/2/3
Cholangiocarcinoma, urothelial cancer (phase 3 in the US) China
IBI-376 (parsaclisib) PI3Kδ NHL (phase 2 in the US) China
IBI-306 PCSK9Metabolic: homozygous familial hyperlipidemia; statin intolerant high CV risk
patientsChina
IBI-362 OXM3 Metabolic: diabetes China
IBI-310 CTLA-4 Oncology: melanoma and renal cell carcinoma Worldwide
IBI-101 OX40 Oncology: advanced solid tumors, hepatitis B Worldwide
IBI-188 CD47 Oncology: B-cell lymphoma, ovarian cancer, colorectal cancer Worldwide
IBI-318 PD-1/PD-L1 Oncology: advanced tumors (undisclosed target) China
IBI-302 VEGF/Complement proteins Ophthalmology: wet AMD Worldwide
IBI-110 LAG-3 Oncology: NSCLC, melanoma, mBrCA, advanced tumors Worldwide
IBI-315 PD-1/HER2 Oncology: Her2 + cancers, mBrCA, gastric cancer, NSCLC Worldwide
IBI-326 BCMA-CART Oncology: Relapsed/Refractory Multiple Myeloma Worldwide
IBI-319PD-1/
undisclosed targetOncology: advanced tumors (undisclosed target) China
IBI-322 PD-L1/CD47 Oncology: PDL1/CD47 coexpressing tumors, M1 macrophage signature tumors Worldwide
IBI-939 TIGIT Oncology: advanced solid tumors worldwide
IBI-323 LAG-3/PD-L1 Oncology: PDL1+ tumors with “hot tumor” phenotype Worldwide
IND approved: Dec 2016
IND approved: Sep 2017
IND approved: Jun 2019
NDA filed: Jan 2019
NDA filed: Nov 2018
NDA filed: Jun 2019
IND approved: Feb 2018
IND approved: Jun 2018
IND approved: Feb 2019
IND approved: Aug 2018
Biologics Small molecules
NDA approved: Dec 24, 2018
Robust Pipeline across Biologics and Small Molecules
Clinical progress in the U.S.
IND approved: July 2019
5Copyright© 2019 Innovent Biologics
Clinical Highlights of Sintilimab (Tyvyt®) andIBI-303 (Adalimumab Biosimilar)
Cover Story of Sintilimab (Tyvyt®)by The Lancet Haematology
Published at Inaugural Issue of The Lancet Rheumatology
Equivalence trial between IBI-303 and adalimumab
The first China based Phase III report of biosimilar appears in the first-tier medical journal
Registration trial in 96 patients with relapsed or refractory classical Hodgkin’s lymphoma
80.4% ORR, 34% CR
6Copyright© 2019 Innovent Biologics
Agenda
1 Commercialization of Sintilimab - Tyvyt®
2 Manufacturing Facility
3 Global Partnership
4 Organization
7Copyright© 2019 Innovent Biologics
Commercialization of Sintilimab Injection - Tyvyt®
SALES LAUNCHEDTyvyt® (sintilimab injection)
RMB331.6 MSales reached
1H 2019
March 9, 2019
8Copyright© 2019 Innovent Biologics
Stronger Brand to Generate Greater Demands
Commercial Strategy
BROADEN MARKET
PENETRATION & INCREASE
ACCESSIBILITY
• Broaden coverage to lower-tier cities
• Expand DTP and hospital formulary accessibility
• Implement patient benefit program tofurther relievepatients’ financialburden
STRENGTHEN SHARE OF
VOICE
• Further expand sales force
• Launch marketing campaigns for Tyvyt® and Bevacizumab biosimilar launch to strengthen brand loyalty
• Improve positive clinical experiences
BUILD RECOGNITION & LEADERSHIP
• Listed into CSCO 2019 treatment guideline
• Support clinical studies: WJP/CSCO research funds
• Work with KOLs and medical society to generate data through IIS & RS studies
• Play leading role in supporting the market education cross major disease areas
9Copyright© 2019 Innovent Biologics
Build a Strong Competitive and ProfessionalSales Force with Scale by End of 2019
30ProvincesCoverage
~300Cities
Coverage
~1,500Target Hospital
~400DTP/Pharmacies
~800Commercial Team
Size
10Copyright© 2019 Innovent Biologics
Clinical Development Programs for Sintilimab
Status
Indication1, 2, 3Mono-/Combo-Therapy (Other
Components)
Phase I
Phase II Phase III
NDA
Filed
NDA
ApprovedIa Ib
China
r/r Classical Hodgkin’s Lymphoma Mono
2L Classical Hodgkin’s Lymphoma Combo (ICE)
2L Squamous NSCLC Mono
1L Squamous NSCLC Combo (gemcitabine and platinum)
1L Non-squamous NSCLC Combo (pemetrexed and platinum)
EGFR + TKI Failure NSCLC Combo (IBI-305)
1L Hepatocellular Carcinoma Combo (IBI-305)
1L Gastric Cancer Combo (capecitabine and oxaliplatin)
1L Esophageal Carcinoma Combo (paclixel and cisplatin)
2L ESCC Mono
r/r NK/T-cell Lymphoma Mono
2L NSCLC Mono
1L/2L Melanoma Mono
Refractory Gastrointestinal Cancer Mono
2L Neuroendocrine Tumor Mono
1L Squamous NSCLC Combo (gemcitabine and cisplatin)
1L Gastric Cancer Combo (capecitabine and oxaliplatin)
Refractory Solid Tumors Mono
U.S.
Solid Tumors Mono
Late Stage Endometrial Carcinoma Mono
Notes1 Abbreviations: r/r = relapsed, refractory; 2L = second-line; 1L = first-line; NK/T-cell lymphoma = natural killer/T-cell lymphoma; ESCC = esophageal squamous cell carcinoma; NSCLC = non-small cell lung
cancer; EGFR = epidermal growth factor receptor; TKI = tyrosine kinase inhibitor.2 Symbols: = completed; = completed patient enrollment; = in progress; = to be initiated within next quarter.3 Some indications may not require every clinical trial indicated on this chart to completed prior to the filing of an NDA.
11Copyright© 2019 Innovent Biologics
1 Commercialization of Sintilimab - Tyvyt®
2 Manufacturing Facility
3 Global Partnership
4 Organization
Agenda
12Copyright© 2019 Innovent Biologics
State-of-the-art Manufacturing Facilities Designed to, Built to and Operating at International Standards
M1b Facility: GMP commissioning and validation completed
4 x 15,000 L Planned
5 x 1,000 L In Operation6 x 3,000 L (cGMP validated) Ready in 2019
Total capacity in the future: 83KL
On 29 December 2018, our manufacturing facilities received GMP certification from the NMPA for manufacturing Tyvyt® (sintilimab)
Innovent’s manufacturing facilities
are designed complied with FDA,
EMA and NMPA standards, and
support the full process from DS to
DP. DS, DP and GMP were
successfully audited.
Undergone ordinary course,
comprehensive annual audits of
production facility to evaluate
compliance with industry GMP
and quality compliance standards.
Manufacturing team with
extensive experience at multi-
national pharmaceutical companies.
13Copyright© 2019 Innovent Biologics
1 Commercialization of Sintilimab - Tyvyt®
2 Manufacturing Facility
3 Global Partnership
4 Organization
Agenda
14Copyright© 2019 Innovent Biologics
Global Partners
July 2013
• Therapeutic antibody
discovery platform
November 2018
• Combination therapy
June 2016
• Bispecific antibody
platform
February 2019
• Combination therapyMarch 2017
• Bispecific antibody collaboration
December 17th , 2018
• Multi-product strategic collaboration
with Incyte
• Licensed in 3 potentially best-in-class
clinical-stage product candidates
for China development and
commercialization
• Transformed Innovent from a mAb
development focused company to a
broader portfolio oncology
focused entity
August 22th, 2019
• Licensed in Lilly’s mid-stage potentially global best-in-class diabetes productcandidate for China development and commercialization
October 12th, 2015
• Licensed out ex-China right of additional 3 PD-1 bispecific mAbs to Lilly
• Potential milestones >$1 billion
March 20th, 2015
• Licensed out PD-1 mAb ex-China to Lilly
• Co-development of 3 mAbs in China
• Received upfront payment of $56 M and potential milestones >$0.4 Bn
July 2019
• Combination therapy
15Copyright© 2019 Innovent Biologics
OXM3Licensed in a mid-stage potentially global best-in-class diabetes
molecule product candidate for China development and
commercialization
Expanded efforts in metabolic diseases into the diabetes area
Deeper Collaboration with Lilly
3 PD-1 bispecific mAbsLicensed out ex-China right of additional 3 PD-1 bispecific
mAbs to Lilly
May receive milestones >$1 billion
3 mAbs , including PD-1 mAbLicensed out PD-1 mAb ex-China to Lilly, Co-development of 3
mAbs in China
Received upfront payment of $56 mm and may receive milestones >$0.4 bn
16Copyright© 2019 Innovent Biologics
RATIONALE
Strengthen our metabolic portfolio with a first in China, potentially global best-in-class molecule that will be a strong entry point for Innovent to enter into diabetes, an attractive fast growing therapeutic area
Licensed-in Lilly’s Mid-stage Diabetes Molecule OXM3
PRODUCT
• OXM3 is an engineered analog of Oxyntomodulin, a naturally occurring 37-amino acid peptide hormone
• OXM3 is a dual-agonist that targets both the GLP-1 receptor and the Glucagon receptor• OXM3 is a weekly administered injectable that is expected to offer strong glucose lowering
and Best-in-Class weight loss – addressing an unmet need for a large portion of type 2 diabetes patients
TERMS
• Receives development and commercialization rights to Lilly’s mid-phase diabetes product, OXM3
• Lilly retains ex-China rights• OXM3 is currently in active development by Lilly as a Phase II ready asset• Financial terms have not been disclosed
17Copyright© 2019 Innovent Biologics
1 Commercialization of Sintilimab - Tyvyt®
2 Manufacturing Facility
3 Global Partnership
4 Organization
Agenda
18Copyright© 2019 Innovent Biologics
Organization Growth
1. As of June 30, 2019
COMMERCIALIZATION TEAM R&D TEAMCMC MANUFACTURING & QUALITY
TEAMGENERAL AND ADMINISTRATIVE
TEAM
1,500Organization Growth to Approximately 1,500 Employees1
450 530 400 120
19Copyright© 2019 Innovent Biologics
Awards
Industry-wide Recognition
LACP 2018
Vision Awards
- Gold Award
2018
Annual
Achievement
Award
10th
Anniversary
CHIC
IPO of the Year
2019 Gelonghui
Best Listed
Companies
Award
20Copyright© 2019 Innovent Biologics
2019 Outlook
1 2
3 4
2019
SALES GROWTH
Anticipate to continue the
strong sales momentum for
the remainder of 2019
PRODUCT LAUNCH PREPARATION
• Actively engage with the NMPA for the NDAs approval process for IBI-303, IBI-305 & IBI-301
• Commercial preparation for products launch
CLINICAL ADVANCEMENT
Continuous clinical advancement including 8 pivotal registration trials, late stage clinical trials and a number of drug candidates
MANUFACTURING
Planning to further expand manufacturing
facilities to provide sufficient capacity
commensurate with our growing and
maturing drug pipeline
21Copyright© 2019 Innovent Biologics
• Tyvyt® launched sales
• 3 NDAs filed (IBI-303, IBI-305 & IBI-301)and under review by the NMPA withpriority review status
• Extending product portfolio to diabetesarea through licensing in Eli Lilly’s OXM3
• M1b:6*3000L bridging
• 4 commercialized products
• 5 products entering late stage development
• Global R&D platform
2
VISION
5-year Plan with Measurable Goals
• >8 commercialized products
• Multiple products entering late clinical stage
• Larger GMP manufacturing capacity
3
20252021
2019
22Copyright© 2019 Innovent Biologics